Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 18/20 | 0.66 |
| ▸ | CNR2 | P34972 | 17/20 | 0.66 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30961559 | 1.00 | CNR1 (0.66) | CNR1CNR2GABRA2GABRB2HTR2A | |
| SCHEMBL1040785 | 0.93 | CNR1 (0.74) | CNR1CNR2 | |
| SCHEMBL4510377 | 0.92 | CNR1 (0.55) | CNR1CNR2GABRA2GABRB2HTR2A | |
| SCHEMBL4615166 | 0.90 | CNR1 (0.67) | CNR1CNR2 | |
| SCHEMBL24238334 | 0.89 | CNR1 (0.66) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL30961585 | 0.89 | CNR1 (0.66) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL2627953 | 0.89 | CNR1 (0.52) | CNR1CNR2GABRA2GABRB2HTR2A | |
| SCHEMBL2627952 | 0.89 | CNR1 (0.55) | CNR1CNR2GABRA2GABRB2HTR2A | |
| SCHEMBL4501713 | 0.88 | CNR1 (0.65) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL4509692 | 0.87 | CNR1 (0.68) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383885-A1 | Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose | MAKSCIENTIFIC, LLC | 2024-11-21 | — | — | US | disclosed |
| US-20230234928-A1 | Novel Compounds for Treating Fibrosis and Inflammatory Conditions | MAKSCIENTIFIC, LLC | 2023-07-27 | — | — | US | disclosed |
| US-20230234928-A1 | Novel Compounds for Treating Fibrosis and Inflammatory Conditions | MAKSCIENTIFIC, LLC | 2023-07-27 | — | — | US | disclosed |
| US-20230234928-A1 | Novel Compounds for Treating Fibrosis and Inflammatory Conditions | MAKSCIENTIFIC, LLC | 2023-07-27 | — | — | US | disclosed |
| WO-2022026478-A1 | NOVEL COMPOUNDS FOR TREATING FIBROSIS AND INFLAMMATORY CONDITIONS | MAKSCIENTIFIC, LLC (US) | 2022-02-03 | — | — | WO | disclosed |
| US-20220033393-A1 | Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose | MAKSCIENTIFIC, LLC | 2022-02-03 | — | — | US | disclosed |
| US-20220033393-A1 | Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose | MAKSCIENTIFIC, LLC | 2022-02-03 | — | — | US | disclosed |
| WO-2022026478-A1 | NOVEL COMPOUNDS FOR TREATING FIBROSIS AND INFLAMMATORY CONDITIONS | MAKSCIENTIFIC, LLC (US) | 2022-02-03 | — | — | WO | disclosed |
| US-8853205-B2 | Heteropyrrole analogs acting on cannabinoid receptors | UNIVERSITY OF CONNECTICUT (US) | 2014-10-07 | — | — | US | disclosed |
| US-8410097-B2 | Heteropyrrole analogs acting on cannabinoid receptors | UNIVERSITY OF CONNECTICUT (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2398323-A1 | NOVEL HETERO PYRROLE ANALOGS ACTING ON CANNAPINOID RECEPTORS | University of Connecticut (US) | 2011-12-28 | — | — | EP | disclosed |
| US-8084451-B2 | Heteropyrrole analogs acting on cannabinoid receptors | UNIVERSITY OF CONNECTICUT (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084451-B2 | Heteropyrrole analogs acting on cannabinoid receptors | UNIVERSITY OF CONNECTICUT (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084451-B2 | Heteropyrrole analogs acting on cannabinoid receptors | UNIVERSITY OF CONNECTICUT (US) | 2011-12-27 | — | — | US | disclosed |
| WO-2010104488-A1 | NOVEL HETERO PYRROLE ANALOGS ACTING ON CANNAPINOID RECEPTORS | UNIVERSITY OF CONNECTICUT (US) | 2010-09-16 | — | — | WO | disclosed |
| US-20100063050-A1 | NOVEL HETEROPYRROLE ANALOGS ACTING ON CANNABINOID RECEPTORS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2010-03-11 | — | — | US | disclosed |
| US-20100063050-A1 | NOVEL HETEROPYRROLE ANALOGS ACTING ON CANNABINOID RECEPTORS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2010-03-11 | — | — | US | disclosed |
| US-20100063050-A1 | NOVEL HETEROPYRROLE ANALOGS ACTING ON CANNABINOID RECEPTORS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2010-03-11 | — | — | US | disclosed |
| EP-1845972-A2 | NOVEL HETEROPYRROLE ANALOGS ACTING ON CANNABINIOD RECEPTORS | University of Connecticut (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006074445-A2 | NOVEL HETEROPYRROLE ANALOGS ACTING ON CANNABINIOD RECEPTORS | MAKRIYANNIS ALEXANDROS (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383885-A1 | Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose | CNR1, CNR2, OPRM1 | CNR1 1/4885CNR2 2/4885GABRA2 455/4885 |
| US-20220033393-A1 | Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose | CNR1, CNR2, OPRM1 | CNR1 1/4885CNR2 2/4885GABRA2 455/4885 |
| US-20100063050-A1 | NOVEL HETEROPYRROLE ANALOGS ACTING ON CANNABINOID RECEPTORS | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885GABRA2 40/4885 |
| US-20230234928-A1 | Novel Compounds for Treating Fibrosis and Inflammatory Conditions | CNR2, CNR1, GPR174 | CNR1 2/4885CNR2 1/4885GABRA2 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.